Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Alligator Bioscience AB ( (SE:ATORX) ) is now available.
Alligator Bioscience AB announced the final outcome of its TO 12 warrant exercise, achieving a 71% exercise rate, resulting in the subscription of nearly 14 million new shares. To reach an 85% exercise rate, the company will execute top guarantee commitments, raising approximately SEK 61.5 million, which positions them well for further development and a pivotal Phase 3 trial.
More about Alligator Bioscience AB
Alligator Bioscience AB operates in the biotechnology industry, focusing on developing immunotherapies for cancer treatment. The company is particularly invested in advancing mitazalimab, a potential breakthrough therapy for metastatic pancreatic cancer.
Average Trading Volume: 246,581
Current Market Cap: SEK71M
See more data about ATORX stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money